Estrella Immunopharma (ESLA) Stock: Buy, Sell, or Hold?
ESLA - Estrella Immunopharma, Inc. Common Stock
$0.99
0.26 (35.53%)
▲
5d:
+129.07%
30d:
+109.13%
90d:
+27.13%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When ESLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ESLA is 58.9% above its trading range ($0.62). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ESLA is 58.9% above its trading range ($0.62). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ESLA is currently trading at $0.98, which is considered extended relative to its 30-day fair value range of $0.36 to $0.62.
Technical Outlook: Technically, ESLA is in a strong downtrend. The price is approaching resistance at $1.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 35.5% recently.
Market Sentiment: ESLA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+1118.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ESLA is in a strong downtrend. The price is approaching resistance at $1.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 35.5% recently.
Market Sentiment: ESLA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+1118.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.36 -
$0.62
Company Quality Score
30/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+58.9% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: Strong upward momentum (+35.5%)
- BULLISH: Trading 1118.3% below Wall St target ($12.00)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.36 -
$0.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.24
Resistance Level
$1.00
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.08
Wall Street Target
$12.00
(+1118.3%)
Share & Embed Analysis
Last updated: October 24, 2026 12:48 AM ET
Data refreshes hourly during market hours. Next update: 1:48 AM
Data refreshes hourly during market hours. Next update: 1:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ESLA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
